Start the conversation
I happened to be on the phone with Michael Robinson, our resident tech-investing expert, yesterday when the conversation turned to the biotech sector.
We both like the sector's long-term upside: With the aging U.S. population, the demographic catalyst of the American market alone is a great reason to have a bullish long-term view of bioscience stocks.
And now the sector seems to be rebounding from its recent swoon - meaning there's reason to be bullish in the near-term, too...
This is premium content for Private Briefing subscribers only.